^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
WJ05129
i
Other names: WJ05129, JS112
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shanghai Junshi Biosci, Wigen Biomedicine
Drug class:
Aurora kinase A inhibitor
Related drugs:
2ms
A Study of WJ05129 in Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1/2, N=26, Terminated, Suzhou Junjing BioSciences Co., Ltd. | N=126 --> 26 | Not yet recruiting --> Terminated; The sponsor terminated the study on the basis of the current data and the company's research and development strategy
Enrollment change • Trial termination
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
paclitaxel • WJ05129
over3years
A Study of WJ05129 in Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1/2, N=126, Not yet recruiting, Suzhou Junjing BioSciences Co., Ltd.
New P1/2 trial
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
MYC expression • RB1 negative
|
WJ05129
Share via
